Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Yatai Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily serving the Chinese market. The company has a competitive edge due to its strong R&D capabilities and a diverse product portfolio that includes antibiotics and cardiovascular drugs.
Zhejiang Yatai generates revenue through the sale of generic and specialty drugs, leveraging its strong R&D capabilities to produce cost-effective alternatives to branded medications. The company's competitive advantages include a robust pipeline of products and established relationships with healthcare providers in China.
Regulatory approvals for new drug formulations
Changes in healthcare policies affecting drug pricing
Market share shifts in the Chinese pharmaceutical sector
R&D breakthroughs leading to new product launches
Regulatory changes impacting drug approvals and pricing
Technological disruption in drug manufacturing processes
Intense competition from both domestic and international generic drug manufacturers
Potential for price erosion in the generic drug market
Low liquidity due to zero operating and free cash flow
Dependence on continued R&D funding for product development
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP growth.
Low - The company's low debt levels minimize the impact of rising interest rates on financing costs.
minimal - The company's strong balance sheet reduces reliance on credit.
growth - Investors looking for growth opportunities in the pharmaceutical sector may find Yatai appealing due to its R&D focus.
moderate - The stock has shown significant price fluctuations, evidenced by a 1-year return of 40.5%.
